$0.8743
-0.027-3%
Last update: Nov 10, 7:56 PM
Annovis Bio Inc
ANVSNYSE
Annovis Bio fell 54.7% from $1.99 to $0.90, behind the S&P 500's +10.0%. Its worst day was Nov 5 (−44.7%), and its low came Nov 5 at $0.67.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.37 beat the $-0.37 estimate on $0.00 revenue.
+15.2% · S&P 500 +0.1%
Annovis Bio closed at its highest level of the year, 156.3% above where the year started.
Story events cover the past 12 months · Times ET
+3.7% · S&P 500 +0.5%
EPS of $-0.39 missed the $-0.34 estimate on $0.00 revenue.
+12.3% · S&P 500 +1.0%
Annovis Bio shares fell 29.6%, while the S&P 500 rose 0.6%.
−29.6% · S&P 500 +0.6%
EPS of $-0.63 missed the $-0.35 estimate on $0.00 revenue.
−3.3% · S&P 500 −1.2%
EPS of $-0.40 beat the $-0.46 estimate on $0.00 revenue.
+3.4% · S&P 500 −0.2%
Annovis Bio shares fell 18.8%, while the S&P 500 rose 1.0%.
−18.8% · S&P 500 +1.0%
Where it ended: a close of $0.90 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.32).
Nothing in the past 12 months.
All ANVS dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ANVS and SPY from Benzinga historical bars. Not investment advice.
